This study is a first in human, Phase 1, open label, multicenter, dose escalation study of AMV564 in patients with relapsed or refractory AML. Patients must have documented diagnosis of AML according to World Health Organization (WHO) criteria. After providing signed informed consent, patients will be screened for entry into the study. The study will be conducted in 2 stages. In a dose escalation stage, approximately 32 patients will be enrolled. Escalation cohorts of 3 to 6 patients will receive repeat doses of AMV564 to determine the MTD and RP2D. AMV564 will be administered daily for 14 days. In a second expansion phase, a total of 18 patients will receive AMV564 at the established RP2D.